SCREENING FOR SUBSTANCE USE DURING PREGNANCY: USING AN SBIRT FRAMEWORK



Developing a Screening, Brief Intervention, and Referral to Treatment (SBIRT) process in the maternity care context

Note: While some medical tests may be used for both screening and diagnostic purposes, the terms are not interchangeable. Screening may occur in any healthcare setting to identify health risk behaviors, including substance use.

SBIRT implementation requires modification of existing clinic workflows. Each context is different. SBIRT should be incorporated into the existing intake process for new OB patients, which includes screening for other medical risks.

Brief description of a typical SBIRT implementation process



SBIRT Preparation

- Review institutional policies and update as needed to include use of the SBIRT framework for prenatal patients
- Develop a plan for modifying workflow to incorporate screening
- Train appropriate staff on screening process
- Train appropriate staff in brief intervention techniques
- Identify follow-up plan and key personnel for when screening is positive
- Create a list of resources to support women in need of referrals for substance use
- · Identify billing requirements and opportunities
- Develop patient information script or written materials about substance use screening and institutional policies on substance use



2


Implementation

- Implement workflow modification to include confidential screening and response
- Provide information about institutional substance use policies as part of new patient orientation
- Screen using a validated questionnaire on paper or electronically
- Ensure a warm handoff occurs from staff performing screening to staff who will address positive screening results
- Implement Brief Negotiated Interview (BNI) algorithm following positive screening
- Develop a follow-up plan when screening is positive
- Make referrals if needed



Learn more: opqic.org/omno

ALGORITHM FOR SUBSTANCE ABUSE SCREENING IN PREGNANCY



Declines screening, or negative screening, but presence of **neonatal** complications associated with substance use (positive NAS scoring, anomalies suggestive of drug or alcohol exposure, vascular accidents, MI, NEC at term): Perform neonatal biochemical testing and monitor for NAS.

*Antenatal risk factors: no or inadequate prenatal care; exhibited signs and symptoms of drug and/or alcohol use or withdrawal; drug-seeking behavior; repeated use of prescription narcotics; personal history of domestic violence, incarceration, or child welfare referrals; hepatitis B/C; HIV-positive status; active STIs; unexplained preterm labor; placenta abruption; FGR; hypertension

Learn more: opqic.org/omno

This publication was supported by cooperative agreements 6 NU17CE002745-04 and 1 NB010T009219-01 from the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Department of Health and Human Services. This publication was issued by the Oklahoma State Department of Health, an equal opportunity employer and provider. 90,000 were printed by Mercury Press Plus at a cost of \$3,742.84. A digital file has been deposited with the Publications Clearinghouse of the Oklahoma Department of Libraries in compliance with section 3-114 of Title 65 of the Oklahoma Statutes and is available for download at www.documents.ok.gov. | Issued August 2019. Adapted with permission from the Illinois Perinatal Quality Collaborative



